阿片类药物市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

全球阿片类药物市场按产品类型(可待因、芬太尼、吗啡、哌替啶、美沙酮和其他产品类型)、受体结合(强激动剂和轻度至中度激动剂)、应用(疼痛管理(癌症疼痛、神经性疼痛、骨关节炎)细分疼痛和其他疼痛管理)、感冒和咳嗽、腹泻和其他应用)和地理(北美、欧洲、亚太地区、中东和非洲以及南美)。该报告提供了上述细分市场的价值(以百万美元计)。

市场快照

Opioids Market Overview
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 3.5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

2020 年全球阿片类药物市场价值约为 198.69 亿美元,预计 2026 年将达到 244.35 亿美元,预测期内复合年增长率为 3.5%。

在全球范围内,COVID-19 大流行在整个医疗领域显示出许多负面影响,其中包括面对面预约的减少和远程医疗就诊的增加。COVID-19 大流行还导致了一段隔离期,以保持医院足够的容量并减少病毒的传播。慢性疼痛是 COVID-19 大流行中受灾最严重的领域之一,许多患者的慢性疼痛负担过重,正在进行的治疗被推迟。例如,根据 Rajendra K Sahoo 等人在《印度麻醉杂志 2020》上发表的一篇研究文章,研究结果发现,63.16% 的疼痛医师害怕将疾病传播或感染给患者家属,26.79 % 的人睡眠受损,1.43% 的医生感到沮丧,8.14% 的医生感到焦虑。

推动市场增长的其他一些主要因素包括导致慢性疼痛的疾病日益流行,例如癌症、关节炎、下背痛、纤维肌痛和术后疼痛,从立即释放阿片类药物中转向缓释制剂的倾向,以及仿制药制造商越来越关注滥用威慑配方 (ADF)。

阿片类药物被认为是治疗疼痛的最有效药物。此外,它们在治疗慢性疼痛中的应用被认为是世界大部分地区的标准做法。由于医疗疾病负担的增加,预计阿片类药物市场将在预测期内增长。

此外,阿片类药物在术后环境中发挥关键作用,以提供足够的镇痛作用。根据 2020 年疾病控制和预防中心的数据,美国有超过 3250 万患者受到骨关节炎的影响。在英国,骨关节炎的发病率稳步上升。根据 Versus Arthritis,在 2019 年,据估计,英格兰 45 岁以上的人中有超过 18% 的人患有膝关节骨关节炎。

根据 Eugenio Cavalli 等人发表在 2019 年国际免疫病理学和药理学杂志上的研究文章,全球一般人群中神经性疼痛的患病率估计在 3%-17% 之间。因此,阿片类药物治疗是中度至重度疼痛患者骨科治疗的中流砥柱,这有助于推动市场的整体增长。然而,大麻作为阿片类药物和处方药滥用的替代品的出现和合法化等因素预计将阻碍预测期内的市场增长。

报告范围

根据报告,阿片类药物是一类作用于神经系统以减轻疼痛的药物。它们主要用于缓解疼痛和麻醉。全球阿片类药物市场按产品类型(可待因、芬太尼、吗啡、哌替啶、美沙酮和其他产品类型)、受体结合(强激动剂和轻度至中度激动剂)、应用(疼痛管理(癌症疼痛、神经性疼痛、骨关节炎疼痛和其他疼痛管理)、感冒和咳嗽、腹泻和其他应用)和地理(北美、欧洲、亚太地区、中东和非洲以及南美)。该报告提供了上述部分的价值(以百万美元计)。

By Product Type
Codeine
Fentanyl
Morphine
Meperidine
Methadone
Other Product Types
By Receptor Binding
Strong Agonist
Mild to Moderate Agonist
By Application
Pain Management
Cancer Pain
Neuropathic Pain
Osteoarthritis Pain
Other Pain Managements
Cold and Cough
Diarrhoea
Other Applications
Geography
North America
United States (by Product Type, Receptor Binding, and Application)
Canada (by Product Type, Receptor Binding, and Application)
Mexico (by Product Type, Receptor Binding, and Application)
Europe
Germany (by Product Type, Receptor Binding, and Application)
United Kingdom (by Product Type, Receptor Binding, and Application)
France (by Product Type, Receptor Binding, and Application)
Italy (by Product Type, Receptor Binding, and Application)
Spain (by Product Type, Receptor Binding, and Application)
Rest of Europe (by Product Type, Receptor Binding, and Application)
Asia-Pacific
China (by Product Type, Receptor Binding, and Application)
Japan (by Product Type, Receptor Binding, and Application)
India (by Product Type, Receptor Binding, and Application)
Australia (by Product Type, Receptor Binding, and Application)
South Korea (by Product Type, Receptor Binding, and Application)
Rest of Asia-Pacific (by Product Type, Receptor Binding, and Application)
Middle-East and Africa
GCC (by Product Type, Receptor Binding, and Application)
South Africa (by Product Type, Receptor Binding, and Application)
Rest of Middle-East and Africa (by Product Type, Receptor Binding, and Application)
South America
Brazil (by Product Type, Receptor Binding, and Application)
Argentina (by Product Type, Receptor Binding, and Application)
Rest of South America (by Product Type, Receptor Binding, and Application)

Report scope can be customized per your requirements. Click here.

主要市场趋势

强激动剂预计将在受体结合领域占有重要的市场份额

激动剂是一种药物分子,可触发大脑中的某些受体。当只有相对较少数量的受体被占据时,即药物具有高内在活性时,这种激动剂会产生显着的生理/药理学反应。强效阿片类药物包括芬太尼、吗啡、二氢吗啡酮、哌替啶、羟考酮和羟吗啡酮。

在全球范围内,COVID-19 造成了健康危机。在全球范围内的 COVID-19 大流行期间,卫生机构从事预防感染并向 COVID-19 患者提供服务,导致取消选择性手术和选择性会诊,这对医院和疼痛诊所的疼痛服务产生了影响.

美沙酮是一种强效激动剂,可有效治疗阿片类药物(如海洛因)成瘾。强效激动剂与阿片受体紧密结合,从而发生显着的构象变化。

在全球范围内,许多人在日常生活中都经历过痛苦。例如,根据加拿大慢性疼痛协会 (CPAC) 2019 年报告估计,慢性疼痛患者的生活质量随着疼痛的增加而下降。此外,17-31% 的人报告有慢性疼痛。50% 的住院患者报告有中度至重度强度的急性疼痛。慢性疼痛管理的年度直接医疗费用在每名患者 10,000-14,000 美元之间。

市场参与者采用各种策略,例如产品批准和开发,以扩大其产品组合、扩展、合作和合并,以增加市场份额。例如,2018 年 11 月,AcelRx Pharmaceuticals Inc. 获得美国 FDA 批准的 DSUVIA(Dsuvia 是一种阿片类镇痛药物,其效力约为其母体药物芬太尼的 5 至 10 倍,效力为吗啡的 500 倍)用于在经过认证的医学监督医疗机构中的成年人,用于治疗严重到需要使用阿片类镇痛剂的急性疼痛。因此,预计上述因素将在不久的将来推动该细分市场的增长。

Opioids Market Latest Trends

北美主导市场,预计在预测期内将继续主导

推动北美市场增长的主要因素包括骨科疾病发病率上升、癌症和糖尿病等慢性病患病率上升、可支配收入增加和老年人口激增,以及该地区主要市场参与者的存在.

在美国,COVID-19 大流行迫使医疗保健系统将医疗资源重新分配给 COVID-19 专用站点和重症监护病房。在 2020 年 COVID-19 大流行期间,非紧急、门诊和选择性介入程序的慢性疼痛服务在 COVID-19 大流行期间减少或中断,以降低病毒传播的风险。

根据 Filomena Puntillo 等人发表在 Best Practice and Research: Clinical Anesthesiology Journal 2020 上的一篇研究文章,慢性疼痛人群仍然与世隔绝,从而产生社会和心理影响。由于美国政府在 COVID-19 大流行期间实施的封锁,疼痛服务的关闭影响了慢性疼痛管理。

随着癌症疼痛患者人数的增加,美国癌症幸存者的人数正在迅速增长,这推动了市场的增长。例如,根据蒋长川等人在 JAMA Oncology Journal 2019 上发表的一篇研究文章,根据研究结果,在 4,526 名癌症幸存者中,有 1,648 名受试者报告患有慢性疼痛,768 名受试者患有高影响慢性疼痛。 HICP),分别代表约 539 万和 251 万癌症幸存者。

根据加拿大政府的数据,2019 年,该国约有 763 万人患有慢性疼痛。在加拿大,慢性疼痛对身心健康、家庭和社区生活以及经济产生了重大影响,2019 年的直接和间接总成本为 38.3 美元至 404 亿美元。

吗啡和可待因是治疗癌症疼痛最常用的阿片类药物。2018 年,美国食品药品监督管理局启动了 2018 年战略政策路线图,旨在减少阿片类药物的误用和滥用。因此,预计上述因素将在预测期内显示出显着的市场增长。

Opioids Market Growth Rate By Region

竞争格局

阿片类药物市场分散且竞争激烈。市场由几个参与者组成。然而,随着阿片类药物在药物中使用量的增加,越来越多的公司正试图进入这个市场,尤其是在新兴市场。然而,严格的法律和严格的监管政策正在阻碍中小企业的市场渗透。一些市场参与者包括 Teva Pharmaceuticals Inc.、Mallinckrodt Pharmaceuticals、Amneal Pharmaceuticals Inc.、Hikma Pharmaceuticals PLC 和 Purdue Pharmaceuticals LP 

竞争格局

阿片类药物市场分散且竞争激烈。市场由几个参与者组成。然而,随着阿片类药物在药物中使用量的增加,越来越多的公司正试图进入这个市场,尤其是在新兴市场。然而,严格的法律和严格的监管政策正在阻碍中小企业的市场渗透。一些市场参与者包括 Teva Pharmaceuticals Inc.、Mallinckrodt Pharmaceuticals、Amneal Pharmaceuticals Inc.、Hikma Pharmaceuticals PLC 和 Purdue Pharmaceuticals LP 

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Prevalence of Orthopedic Diseases and Chronic Pain

      2. 4.2.2 Inclination toward Extended Release Formulations from Immediate Release of Opioids

      3. 4.2.3 Rising Focus on Abuse-deterrent Formulation (ADF) by Generic Manufacturers

    3. 4.3 Market Restraints

      1. 4.3.1 Advent and Legalization of Cannabis as an Alternative to Opioids

      2. 4.3.2 Prescription Drug Abuse

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Product Type

      1. 5.1.1 Codeine

      2. 5.1.2 Fentanyl

      3. 5.1.3 Morphine

      4. 5.1.4 Meperidine

      5. 5.1.5 Methadone

      6. 5.1.6 Other Product Types

    2. 5.2 By Receptor Binding

      1. 5.2.1 Strong Agonist

      2. 5.2.2 Mild to Moderate Agonist

    3. 5.3 By Application

      1. 5.3.1 Pain Management

        1. 5.3.1.1 Cancer Pain

        2. 5.3.1.2 Neuropathic Pain

        3. 5.3.1.3 Osteoarthritis Pain

        4. 5.3.1.4 Other Pain Managements

      2. 5.3.2 Cold and Cough

      3. 5.3.3 Diarrhoea

      4. 5.3.4 Other Applications

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States (by Product Type, Receptor Binding, and Application)

        2. 5.4.1.2 Canada (by Product Type, Receptor Binding, and Application)

        3. 5.4.1.3 Mexico (by Product Type, Receptor Binding, and Application)

      2. 5.4.2 Europe

        1. 5.4.2.1 Germany (by Product Type, Receptor Binding, and Application)

        2. 5.4.2.2 United Kingdom (by Product Type, Receptor Binding, and Application)

        3. 5.4.2.3 France (by Product Type, Receptor Binding, and Application)

        4. 5.4.2.4 Italy (by Product Type, Receptor Binding, and Application)

        5. 5.4.2.5 Spain (by Product Type, Receptor Binding, and Application)

        6. 5.4.2.6 Rest of Europe (by Product Type, Receptor Binding, and Application)

      3. 5.4.3 Asia-Pacific

        1. 5.4.3.1 China (by Product Type, Receptor Binding, and Application)

        2. 5.4.3.2 Japan (by Product Type, Receptor Binding, and Application)

        3. 5.4.3.3 India (by Product Type, Receptor Binding, and Application)

        4. 5.4.3.4 Australia (by Product Type, Receptor Binding, and Application)

        5. 5.4.3.5 South Korea (by Product Type, Receptor Binding, and Application)

        6. 5.4.3.6 Rest of Asia-Pacific (by Product Type, Receptor Binding, and Application)

      4. 5.4.4 Middle-East and Africa

        1. 5.4.4.1 GCC (by Product Type, Receptor Binding, and Application)

        2. 5.4.4.2 South Africa (by Product Type, Receptor Binding, and Application)

        3. 5.4.4.3 Rest of Middle-East and Africa (by Product Type, Receptor Binding, and Application)

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil (by Product Type, Receptor Binding, and Application)

        2. 5.4.5.2 Argentina (by Product Type, Receptor Binding, and Application)

        3. 5.4.5.3 Rest of South America (by Product Type, Receptor Binding, and Application)

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Mallinckrodt Pharmaceuticals LLC

      2. 6.1.2 Purdue Pharmaceuticals L.P.

      3. 6.1.3 Rhodes Technologies LP

      4. 6.1.4 Sun Pharmaceutical Industries Ltd

      5. 6.1.5 Teva Pharmaceuticals Inc.

      6. 6.1.6 Vertice Pharma LLC

      7. 6.1.7 Johnson and Johnson

      8. 6.1.8 AbbVie Inc (Allergan PLC)

      9. 6.1.9 Hikma Pharmaceuticals PLC

      10. 6.1.10 Endo Pharmaceuticals Inc.

      11. 6.1.11 Zyla Life Sciences (Egalet Corporation)

      12. 6.1.12 Amneal Pharmaceuticals Inc.

      13. 6.1.13 Pfizer Inc.

      14. 6.1.14 AcelRx Pharmaceuticals Inc

      15. 6.1.15 Archimedes Pharma

      16. 6.1.16 Cadila Healthcare (Sentynl Therapeutics Inc.)

      17. 6.1.17 Alcaliber SA

      18. 6.1.18 Verve Health Care Ltd

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Opioids Market market is studied from 2018 - 2026.

The Global Opioids Market is growing at a CAGR of 3.5% over the next 5 years.

The Global Opioids Market is valued at 19869 Million USD in 2018.

The Global Opioids Market is valued at 24435 Million USD in 2026.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Teva Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Amneal Pharmaceuticals Inc., Hikma Pharmaceuticals PLC, Purdue Pharmaceuticals L.P. are the major companies operating in Global Opioids Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!